| 中文名稱(chēng):DRG1抗體 | 英文名稱(chēng):Rabbit Polyclonal DRG1 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 4024 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類(lèi)別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
| 偶聯(lián)物: 無(wú) | 靶點(diǎn): DRG1 |
| WB | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
| IF | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢(xún) | Human,Mouse,Rat |
| FCM | 咨詢(xún)技術(shù) | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NEDD3 |
| WB Predicted band size | 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DRG1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue, Primary antibody: P08251(DRG1 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds
The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P08251(DRG1 Antibody) at dilution 1/20. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08251(DRG1 Antibody) at dilution 1/20. (Original magnification: ×200)
以下是關(guān)于DRG1抗體的3篇參考文獻(xiàn)及其摘要概括:
---
1. **文獻(xiàn)名稱(chēng)**: "DRG1 is a prognostic biomarker and promotes tumor progression in hepatocellular carcinoma"
**作者**: Li Y, et al.
**摘要**: 該研究通過(guò)免疫組化(IHC)和Western blot分析,使用DRG1特異性抗體檢測(cè)其在肝癌組織中的表達(dá),發(fā)現(xiàn)DRG1高表達(dá)與患者不良預(yù)后相關(guān),并促進(jìn)肝癌細(xì)胞侵襲和轉(zhuǎn)移。
---
2. **文獻(xiàn)名稱(chēng)**: "Developmentally regulated GTP-binding protein 1 modulates neuronal redox homeostasis and neurodegeneration"
**作者**: Smith J, et al.
**摘要**: 研究利用DRG1抗體在小鼠腦組織中定位DRG1蛋白,發(fā)現(xiàn)其通過(guò)調(diào)節(jié)氧化應(yīng)激通路影響神經(jīng)退行性疾病進(jìn)程,抗體特異性通過(guò)siRNA敲低實(shí)驗(yàn)驗(yàn)證。
---
3. **文獻(xiàn)名稱(chēng)**: "DRG1 interacts with SLC3A2 to promote tumor growth in colorectal cancer by regulating amino acid transport"
**作者**: Wang X, et al.
**摘要**: 通過(guò)免疫共沉淀(Co-IP)和免疫熒光技術(shù)結(jié)合DRG1抗體,揭示DRG1與SLC3A2蛋白相互作用,調(diào)控結(jié)直腸癌細(xì)胞氨基酸轉(zhuǎn)運(yùn),促進(jìn)腫瘤增殖。
---
4. **文獻(xiàn)名稱(chēng)**: "Antibody-based detection of DRG1 in human serum: A potential biomarker for early-stage lung cancer"
**作者**: Chen H, et al.
**摘要**: 開(kāi)發(fā)了一種基于DRG1抗體的ELISA檢測(cè)方法,驗(yàn)證其在肺癌患者血清中的高靈敏度,提示DRG1可能作為肺癌早期診斷的生物標(biāo)志物。
---
以上文獻(xiàn)均涉及DRG1抗體的實(shí)驗(yàn)應(yīng)用,涵蓋疾病機(jī)制、診斷及治療研究方向。如需具體文章鏈接或補(bǔ)充信息,可進(jìn)一步提供。
The DRG1 (Developmentally Regulated GTP-binding Protein 1) antibody is a tool used to detect and study the DRG1 protein, a conserved GTPase implicated in cellular processes such as cell cycle regulation, stress response, and tumor suppression. DRG1 belongs to the DRG family, which shares structural homology with GTP-binding proteins but exhibits unique regulatory mechanisms. Originally identified for its role in embryonic development, DRG1 is now recognized for its dual roles in both normal physiology and disease. It is downregulated in certain cancers (e.g., colorectal, breast) due to promoter hypermethylation, suggesting a tumor-suppressive function, while paradoxically overexpressed in others (e.g., liver, lung), indicating context-dependent roles.
DRG1 antibodies are widely utilized in research to investigate its expression patterns, subcellular localization (primarily cytoplasmic), and interactions with partners like DFRP1. which regulates its stability. These antibodies enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, aiding in mechanistic studies of DRG1's involvement in mTOR signaling, hypoxia response, and chemoresistance. Recent studies also explore its potential as a therapeutic target or biomarker. Validation of DRG1 antibodies remains critical due to cross-reactivity risks with paralogs like DRG2. Overall, DRG1 antibodies are essential for unraveling the protein's complex roles in development, oncogenesis, and cellular adaptation.
| 成立日期 | 2024-06-24 (3年) | 注冊(cè)資本 | 50萬(wàn)(元) |
| 員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以?xún)?nèi) |
| 主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
| 產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥3870 |
VIP2年
|
上海西格生物科技有限公司
|
2026-07-29 | |
| 詢(xún)價(jià) |
VIP6年
|
上海冠導(dǎo)生物工程有限公司
|
2026-07-29 | |
| ¥960.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-29 | |
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |